Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose methylprednisolone for severe community-acquired pneumonia
ChiCTR2100045056Phase 4Recruiting
- Sponsor
- Shengli Oilfield Central Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone sodium succinate in community-acquired pneumonia (CAP) (4 arms), sponsored by Shengli Oilfield Central Hospital. Primary endpoints: Oxygenation index and Mortality. Started Jun 2021; status: recruiting.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on ChiCTR2100045056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045056.